342 filings
Page 3 of 18
8-K
nh40m8
14 Jan 15
ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years
12:00am
8-K
oxpc3sw4 4c
7 Jan 15
ARIAD Announces Phase 2 Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015
12:00am
8-K
jlwft84ug3jn135wr58
30 Dec 14
Ariad and Otsuka Announce Co-development and Commercialization Agreement for Iclusig® to Treat Leukemias In Japan and Nine Other Asian Countries
12:00am
8-K
5u2b 6p5x0wzivv
30 Dec 14
Other Events
12:00am
8-K
n6jy4l31asd84t6jce
11 Dec 14
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
12:00am
8-K
opuil7mfyd30hdncy9g
5 Nov 14
ARIAD Reports Third Quarter 2014 Financial Results and Development Progress
12:00am
8-K
ewnywnro1u1
24 Oct 14
ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe
12:00am
8-K
plsxczl1zfi
10 Oct 14
ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology
12:00am
8-K
uf9ulplit5gycua286
29 Sep 14
ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer
12:00am
8-K
icv7x
18 Sep 14
Departure of Directors or Certain Officers
12:00am
8-K
8371o4r 26
27 Aug 14
Other Events
12:00am
8-K
z6fse7hj4214368w4
27 Aug 14
Other Events
12:00am
8-K
rkq352
27 Aug 14
Other Events
12:00am
8-K
i8cyejwm2jgp mt2hkf
8 Aug 14
Other Events
12:00am
8-K
1z07qu 43sgmq0ntshy1
6 Aug 14
ARIAD Reports Second Quarter 2014 Financial Results and Development Progress
12:00am
8-K
bht 08e4d4
26 Jun 14
Departure of Directors or Certain Officers
12:00am
8-K
462klla2 2oavf7emu5b
24 Jun 14
Entry into a Material Definitive Agreement
12:00am
8-K
2dzzjdoax3vook8gacu8
19 Jun 14
Other Events
12:00am
8-K
wjrt3i75ali2tjp
17 Jun 14
Ariad Announces Proposed $175 Million Offering of Convertible Senior Notes Due 2019
12:00am
8-K
bjdcw
5 Jun 14
ARIAD Announces Preliminary Safety and Efficacy Data of Ponatinib in Patients with Newly Diagnosed CML from Discontinued Phase 3 EPIC Trial
12:00am